Mary A. Adams, PhD - Publications
Affiliations: | Anthropology | King's College London, London, UK |
Year | Citation | Score | |||
---|---|---|---|---|---|
2010 | Henry JY, Lu L, Adams M, Meyer B, Bartlett B, Dalgleish AG, Galustian C. Abstract 5386: Lenalidomide enhances the anti-prostate cancer activity of docetaxelin vitroandin vivo Cancer Research. 70: 5386-5386. DOI: 10.1158/1538-7445.Am10-5386 | 0.308 | |||
2010 | Henry JY, Lu L, Adams M, Meyer B, Bartlett B, Dalgleish AG. Abstract A43: Lenalidomide enhances the anti-proliferative activity of docetaxel in in vivo and in vitro models of prostate cancer Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-A43 | 0.306 | |||
2008 | Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4650-7. PMID 18628480 DOI: 10.1158/1078-0432.Ccr-07-4405 | 0.309 | |||
2007 | Bartlett JB, Wu L, Adams M, Schafer P, Muller G, Stirling D. Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab Journal of Clinical Oncology. 25: 3023-3023. DOI: 10.1200/Jco.2007.25.18_Suppl.3023 | 0.304 | |||
2007 | Wu L, Adams M, Schafer P, Muller G, Stirling D, Bartlett BJ. Lenalidomide Enhancement of NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Is Mediated by Granzyme B and FasL and Is Associated with Modification of SHIP-1, PLC-g2 and pERK and Enhanced Chemokine Production. Blood. 110: 4885-4885. DOI: 10.1182/Blood.V110.11.4885.4885 | 0.316 | |||
Show low-probability matches. |